個人檔案
學歷
- 2000 臺灣大學醫學院藥研所博士
- 1996 臺灣大學醫學院藥研所碩士
- 1994 臺北醫學院藥學系學士
經歷
- 2023.08- 臺北醫學大學研究發展處研發長
- 2021.11- 臺北醫學大學新藥開發研究中心主任
- 2017.06- 臺北醫學大學生技醫藥商品化中心主任
- 2018.01-2023.12 臺北醫學大學藥學院院長
- 2015.08-2022.07 臺北醫學大學藥學院生技製藥研究中心主任
- 2013.09-2017.12 臺北醫學大學藥學院副院長
- 2013.08- 臺北醫學大學中草藥臨床藥物研發博士學位學程
- 2013.08- 臺北醫學大學癌症生物學與藥物研發博士學位學程
- 2012.10-2016.12 臺北醫學大學藥物有機合成核心服務實驗室主任
- 2012.08- 臺北醫學大學藥物科學學科教授
- 2012.02-2012.07 臺北醫學大學藥物科學學科副教授
- 2008.02-2012.01 臺北醫學大學藥學系副教授
- 2004.10-2008.01 臺北醫學大學藥學系助理教授
獎項
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
研究興趣
- 抗癌小分子化合物設計與合成
- 有機合成
指紋
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
-
探討膠質母細胞瘤腫瘤生態系統並開發新穎治療策略－抑制MIF受體的雙重機制藥物設計及合成：針對膠質母細胞瘤挑戰(1/3)
Liou, J.-P. (PI)
8/1/25 → 7/31/26
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
-
Design, Synthesis and Bio-evaluation of Allopregnanolone derivatives dual Histone Deacetylase Inhibitors as Glioblastoma Multiforme Therapeutic Agents
Liou, J.-P. (PI)
7/1/25 → 2/28/26
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
Design and development of dual drug-loaded liposomes encapsulating gentamicin and curcumin via microfluidic synthesis: A Box-Behnken experimental approach
Yugatama, A., Chao, F. C., Hsu, M. J., Huang, S. W., Liou, J. P. & Hsieh, C. M., 1月 2026, 於: Journal of Drug Delivery Science and Technology. 115, 107750.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取2 !!Link opens in a new tab 引文 斯高帕斯（Scopus） -
Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor
Tran, H. Y., Sharma, R., Lin, H.-Y., Yeh, T.-Y., Shen, C.-J., Hsu, T.-I. & Liou, J.-P., 2026, 於: Journal of Biomedical Science. 33, 1研究成果: 雜誌貢獻 › 文章 › 同行評審
-
Formulation and administration timing of lipid derivatized JAK-inhibitor and corticosteroid modulate saRNA-LNP inflammation and expression
Bathula, N. V., Casmil, I. C., Friesen, J. J., Yuan, E., Liao, S., Maiti, B., Liou, J. P., Lai, M. J., Li, S. D., Chen, S., Tam, Y. Y. C. & Blakney, A. K., 4月 10 2026, 於: Journal of Controlled Release. 392, 114736.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoids
Narwanti, I., Yu, Z. Y., Sethy, B., Zheng, P. L., Cheng, L. H., Tsai, K. K., Lee, S. B. & Liou, J. P., 1月 5 2026, 於: European Journal of Medicinal Chemistry. 301, 118215.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 !!Link opens in a new tab 引文 斯高帕斯（Scopus） -
A Dual CYP17A1/HDAC6 Inhibitor for Targeted Prostate Cancer Therapy
Tran, H. Y., Lin, C. L., Lin, H. Y., Shen, C. J., Sharma, R., Liou, J. P. & Hsu, T. I., 10月 2025, 於: FASEB Journal. 39, 20, e71152.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 !!Link opens in a new tab 引文 斯高帕斯（Scopus）
資料集
-
Additional file 1: of The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H.-J. (Contributor), Lin, Y.-J. (Contributor), Chao, M.-W. (Contributor), Sung, T.-Y. (Contributor), Wu, Y.-W. (Contributor), Chen, Y.-Y. (Contributor), Lin, M.-H. (Contributor), Liou, J.-P. (Contributor), Pan, S.-L. (Contributor) & Yang, C.-R. (Contributor), Unknown Publisher, 12月 29 2018
DOI: 10.6084/m9.figshare.7531874.v1, https://springernature.figshare.com/articles/Additional_file_1_of_The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/7531874/1
資料集: Dataset
-
Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chang, L.-H. (Contributor), Liou, J.-P. (Creator), Lai, M.-J. (Contributor), Chang, C.-D. (Contributor), Tu, H.-J. (Contributor), Chao, M.-W. (Contributor), Pan, S.-L. (Contributor), Chen, Y.-Y. (Creator) & Teng, C.-M. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202902.v1, https://doi.org/10.6084%2Fm9.figshare.8202902.v1
資料集: Dataset
-
Additional file 3: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202890.v1, https://springernature.figshare.com/articles/Additional_file_3_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202890/1
資料集: Dataset
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
資料集: Dataset
-
Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
資料集: Dataset